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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
magnesium and contribution to normal development of bone pursuant to 
Article 14 of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from IDACE, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via 
the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was 
asked  to  deliver  an  opinion  on  the  scientific  substantiation  of  a  health  claim  related  to  magnesium  and 
contribution to normal development of bone. The food constituent, magnesium, which is the subject of the health 
claim, is sufficiently characterised. Contribution to normal development of bone is a beneficial physiological 
effect for infants and young children. A claim on magnesium and maintenance of normal bone in the general 
population has already been assessed with a favourable outcome. The Panel notes that the role of magnesium on 
bone mineralisation and homeostasis applies to all ages, including infants and young children (from birth to three 
years). The Panel concludes that a cause and effect relationship has been established between dietary intake of 
magnesium  and  contribution  to  normal  development  of  bone.  The  following  wording  reflects  the  scientific 
evidence: “Magnesium contributes to normal development of bone”. The target population is infants and children 
up to three years. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from  IDACE, submitted for authorisation of a health claim  pursuant to 
Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel 
on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to magnesium and contribution to normal development of 
bone. 
The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  referring  to  children’s 
development and health. 
The food constituent that is the subject of the health claim is magnesium, which is a well recognised 
nutrient and is measurable in foods by established methods. The Panel considers that magnesium is 
sufficiently characterised.  
The claimed effect proposed by the applicant is “supports the development of healthy and strong bone 
in children”. The target population proposed by the applicant is “infants (from birth onwards) and 
young  children  (until  three  years  of  age)”.  The  Panel  considers  that  contribution  to  normal 
development of bone is a beneficial physiological effect for infants and young children. 
A claim on magnesium and maintenance of normal bone in the general population has already been 
assessed with a favourable outcome. Some 50 to 60 % of the total body magnesium content in normal 
adults resides in bone as a surface constituent of the hydroxyapatite mineral component of bone. The 
magnesium in bone is readily exchangeable with serum, and therefore it may serve as a reservoir for 
maintaining  a  normal  extracellular  magnesium  concentration.  Magnesium  deficiency  in  animals 
results in decreased bone strength and volume, and impaired bone development.  
The Panel notes that the role of magnesium on bone mineralisation and homeostasis applies to all 
ages, including infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between dietary intake 
of magnesium and contribution to normal development of bone. 
The  following  wording  reflects  the  scientific  evidence:  “Magnesium  contributes  to  normal 
development of bone”. 
The Panel considers that, in order to bear the claim, follow-on formulae should comply with the 
criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally 
complete foods for special medical purposes intended for use by infants and nutritionally complete 
foods for special medical purposes other than those intended for use by infants should comply with 
the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-
based foods for infants and young children should comply with the criteria of composition of these 
foods  as  laid  down  in  Directive  2006/125/EC;  other  foodstuffs  intended  for  infants  and  young 
children should provide at least 15 % of the reference values for nutrition labelling for foods intended 
for infants and young children as laid down in Directive 2006/141/EC. Such amounts can be easily 
consumed as part of a balanced diet. The target population is infants and children up to three years. 
No Tolerable Upper Intake Level has been established for magnesium in this age group. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of healt h claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13  and 14 thereof. In  particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk  claims  and  claims  referring  to  children’s  development  and  health  in  a  Community  list  of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any  supplementary  information  supplied  by  the  applicant  available  to  the  European  Food  Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 14/02/2008. 
  The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
  On 26/03/2008, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 08/05/2013, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 20/06/2013. 
  During  its  meeting  on  11/07/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to magnesium and 
contribution to normal development of bone. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: magnesium and contribution to 
normal development of bone. 
EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of magnesium, a positive assessment of its safety, nor a decision on whether magnesium is, 
or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Magnesium and normal development of bone    
 
 
EFSA Journal 2013;11(7):3331                        5 
INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s  name  and  address:  IDACE  (Association  of  the  Food  Industries  for  Particular 
Nutritional Uses of the European Union), 194, rue de Rivoli, 75001, Paris, France. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is magnesium. 
Health relationship as claimed by the applicant 
According to the applicant, magnesium is generally considered as a key element in the development 
and maintenance of healthy bones: it not only constitutes one of the main mineral components of the 
bone, but also plays a capital role in homeostasis of bone mineralization. Magnesium supports the 
development of healthy and strong bone in children. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “magnesium supports the 
development of strong/healthy bones”.  
As equivalent alternative wordings, the applicant has also proposed: “magnesium/contributes to/is 
involved in/is important for/plays an important role for/is necessary for/participates in/is essential 
for/supports/helps  maintain/the  development  of  strong/healthy  bones/the  normal  development  of 
strong/healthy bones”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants (from birth onwards) and young children 
(until three years of age) as defined in Directive 89/398/EEC on foodstuffs intended for particular 
nutritional uses. The claim should be used on foods that are exclusively intended for the category of 
infants and young children, and in line with the composition laid down in the specific directives 
(Directive 2006/141/EC; Directive 2006/125/EC; Directive 1999/21/EC). 
According to the applicant, the quantity needed to achieve the claimed effect is: 
  For follow-on formulae, the content in magnesium should be within the range set in Directive 
2006/141/EC. 
  For dietary foods for special medical purposes, the content in magnesium should be within the 
range set in Directive 1999/21/EC. 
  For processed cereal-based foods and baby foods, the content in magnesium should be within 
the range set in Directive 2006/125/EC. 
  For processed cereal-based foods and baby foods, the content in magnesium should reach at 
least  15  %  of  the  Nutrient  Reference  Values  set  in  Directive  2006/141/EC  (replacing 
Directive 91/321/EC), i.e. 15 % of 80 mg per 100 g or 100 ml or per serving, as reconstituted. 
  For foods intended for infants and young children other than follow-on formulae, processed 
cereal-based foods and baby foods, the content in magnesium should reach at least 15 % of Magnesium and normal development of bone    
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the Nutrient Reference Values set in Directive 2006/141/EC (replacing Directive 91/321/EC), 
i.e. 15 % of 80 mg per 100 ml product ready for use. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is magnesium, which is a well recognised 
nutrient and is measurable in foods by established methods. 
Magnesium  occurs  naturally  in  foods  and  is  authorised  for  addition  to  foods  (Annex  I  of 
Regulation (EC)  No  1925/2006
5,  Annex  I  of  Directive  2002/46/EC
6,  Annex  III  of 
Directive 2006/141/EC
7,  Annex  IV  of  Directive  2006/125/EC
8,  Directive  2001/15/EC
9).  This 
evaluation applies to magnesium naturally present in foods and those forms authorised for addition to 
foods (Annex II of Regulation (EC) No 1925/2006,  Annex II of Directive 2002/46/EC, Annex III of 
Directive 2006/141/EC, Annex IV of Directive 2006/125/EC, Directive 2001/15/EC). 
The Panel considers that the food constituent, magnesium, which is the subject of the health claim, is 
sufficiently characterised.  
2.  Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “supports the development of healthy and strong bone 
in children”. The target population proposed by the applicant is “infants (from birth onwards) and 
young children (until three years of age)”. 
The Panel considers that contribution to normal development of bone is a beneficial physiological 
effect for infants and young children. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed and Medline using “magnesium” as a search 
term, covering a period from 1950 to 2008, and including studies in healthy children below 15 years 
of age. The applicant identified one human intervention study and two observational studies as being 
pertinent  to  the  health  claim.  The  human  intervention  study  evaluated  the  effect  of  magnesium 
supplementation on bone mass at various skeletal sites in girls aged 8-14 years (Carpenter et al., 
2006). The observational studies investigated the effect of dietary magnesium intake on bone mineral 
content in infants and children (Wang et al., 1999; Bounds et al., 2005). 
The  Panel  has  already  assessed  a  claim  on  magnesium  and  maintenance  of  normal  bone  with  a 
favourable outcome (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009). The 
target population was the general population.  
                                                       
5  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
6  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
7  Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow -on formulae and amending 
Directive 1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33. 
8  Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
9  Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes 
in foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25. Magnesium and normal development of bone    
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The total magnesium content in the body of an infant weighing 3.5 kg is approximately 760 mg, while 
the total amount in an adult man is estimated to be around 27 g. In order to accumulate approximately 
27 g of magnesium from infancy to adulthood, an average daily accretion of about 3.6 mg would be 
necessary during this period (IoM, 1997).  
Some 50 to 60 % of the total body magnesium content in normal adults resides in bone as a surface 
constituent of the hydroxyapatite mineral component of bone. The magnesium in bone is readily 
exchangeable  with  serum,  and  therefore  it  may  serve  as  a  reservoir  for  maintaining  a  normal 
extracellular magnesium concentration (FAO/WHO, 2002). Magnesium deficiency in animals results 
in decreased bone strength and volume, and impaired bone development (Volpe, 2006). 
The Panel notes that the role of magnesium on bone mineralisation and homeostasis applies to all 
ages, including infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between dietary intake 
of magnesium and contribution to normal development of bone. 
4.  Panel’s comments on the proposed wording 
The  Panel  considers  that  the  following  wording  reflects  the  scientific  evidence:  “Magnesium 
contributes to normal development of bone”. 
5.  Conditions and restrictions of use  
The Panel considers that, in order to bear the claim: 
  follow-on formulae should comply with the criteria of composition of follow-on formulae as 
laid down in Directive 2006/141/EC; 
  nutritionally complete foods for special medical purposes intended for use by infants and 
nutritionally complete foods for special medical purposes other than those intended for use by 
infants  should  comply  with  the  criteria  of  composition  of  these  foods  as  laid  down  in 
Directive 1999/21/EC
10; 
  processed cereal-based foods for infants and young children should comply with the criteria 
of composition of these foods as laid down in Directive 2006/125/EC; 
  other foodstuffs intended for infants and young children should provide at least 15 % of the 
reference values for nutrition labelling for foods intended for infants and young children as 
laid down in Directive 2006/141/EC. 
Such amounts can be easily consumed as part of a balanced diet. The target population is infants and 
children up to three years. No Tolerable Upper Intake Level (UL) has been established for magnesium 
in this age group. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food constituent, magnesium, which is the subject of the health claim, is sufficiently 
characterised. 
                                                       
10 Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, p. 
29–36. Magnesium and normal development of bone    
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  The claimed effect proposed by the applicant is “supports the development of healthy and 
strong bone in children”. The target population proposed by the applicant is “infants (from 
birth  onwards)  and  young  children  (until  three  years  of  age)”.  Contribution  to  normal 
development of bone is a beneficial physiological effect for infants and young children.  
  A cause and effect relationship has been established between dietary intake of magnesium and 
contribution to normal development of bone. 
  The following wording reflects the scientific evidence: “Magnesium contributes to normal 
development of bone”. 
  In order to bear the claim follow-on formulae should comply with the criteria of composition 
of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods 
for special medical purposes intended for use by infants and nutritionally complete foods for 
special medical purposes other than those intended for use by infants should comply with the 
criteria  of  composition  of  these  foods  as  laid  down  in  Directive  1999/21/EC;  processed 
cereal-based  foods  for  infants  and  young  children  should  comply  with  the  criteria  of 
composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended 
for  infants  and  young  children  should  provide  at  least  15  %  of  the  reference  values  for 
nutrition  labelling  for  foods  intended  for  infants  and  young  children  as  laid  down  in 
Directive 2006/141/EC. Such amounts can be easily consumed as part of a balanced diet. The 
target population is infants and children up to three years. No UL has been set for magnesium 
in this age group. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on magnesium and normal development of bone pursuant to Article 14 of 
Regulation (EC) No 1924/2006 (Claim serial No: 0080_FR). February 2008. Submitted by IDACE. 
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GLOSSARY/ABBREVIATIONS 
UL    Tolerable Upper Intake Level 
 